Market
Isomorphic Labs raises $5 billion Series C co-led by Greenoaks and Sequoia with a16z joining, while its first AI-designed drugs remain preclinical and no valuation is disclosed
Isomorphic Labs raised $5B in a Series C co-led by Greenoaks and Sequoia. Its drugs are still preclinical and no valuation was disclosed.
Isomorphic Labs said on November 17 it raised $5 billion in a Series C co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining and Alphabet investing again. The company declined to share its valuation, Reuters reported. Its first drug candidates have not entered human trials.
The essentials
- The round: $5 billion, co-led by Greenoaks and Sequoia, with a16z as a new investor, per Isomorphic Labs.
- The backers: all existing investors took part, including Thrive, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund, per the company.
- The valuation: undisclosed, per Reuters; Bloomberg had reported talks at about $50 billion, per other outlets.
- The caveat: Tech Times says no human trial and no named clinical candidate were disclosed; R&D World says the drugs remain preclinical.
What the money is for
The Defiant reports the proceeds will expand its drug-design engine, called IsoDDE, and build the operations needed for clinical trials. R&D World cites a year-end trial target.
Who controls it
R&D World, citing UK Companies House records, says Alphabet holds 75% or more of Isomorphic’s shares and voting rights.
What is not established
- The valuation: not disclosed by the company.
- Whether a candidate will enter human trials by year-end: a target, not confirmed.
- Efficacy of any Isomorphic drug in patients: no clinical data disclosed.
- Each investor’s allocation: not reported.
Summary table
| Point | What is stated as of November 18, 2026 | Source |
|---|---|---|
| Amount | $5 billion Series C | Isomorphic Labs |
| Co-leads | Greenoaks and Sequoia Capital | Isomorphic Labs |
| New investor | Andreessen Horowitz | Reuters |
| Valuation | Not disclosed | Reuters |
| Clinical stage | Preclinical, no human trial disclosed | Tech Times |
FAQ
What is Isomorphic Labs’ valuation?
The company did not disclose it. Bloomberg reported talks at about $50 billion, as relayed by other outlets.
Is any Isomorphic drug in human trials?
Not according to the coverage: Tech Times says no human trial was disclosed.
Who controls the company?
R&D World says Alphabet holds 75% or more, citing Companies House records.
Sources
- Isomorphic Labs: Isomorphic Labs announces Series C investment round (verified 2026-11-18)
- Reuters: AI drug developer Isomorphic raises $5 billion in Series C round (verified 2026-11-18)
- R&D World: Isomorphic Labs raises $5 billion in biotech’s biggest venture round (verified 2026-11-18)
- Tech Times: Isomorphic Labs Raises $5 Billion, Discloses No Human Trial (verified 2026-11-18)
- The Defiant: Isomorphic Labs Raises $5 Billion for AI Drug Design (verified 2026-11-18)
Spotted an error in this article? Report it · Our corrections policy